John C. Lechleiter

Last updated
External videos
Nuvola apps kaboodle.svg Leadership Along the Path We Have Chosen, John Lechleiter, Voices in Leadership, March 31, 2015, Harvard University
Nuvola apps kaboodle.svg Eli Lilly CEO John Lechleiter: ‘Engage People Like Never Before’, 2012, DiversityInc
Nuvola apps kaboodle.svg CNBC interview with John Lechleiter, CEO and Chairman of Eli Lilly, 2010, Committee Encouraging Corporate Philanthropy

John C. Lechleiter (born 1952) is an American businessman and chemist. [1] [2] He served as the President, Chief Executive Officer and Chairman of the Board of Directors of Eli Lilly and Company from April 2008 to December 2016. [1] [2] [3] [4] [5] [6] [7] John Lechleiter's successor is David Ricks who assumed the role of president and CEO in January 2017. [8] He is the eldest of nine children of Jeanne and John H. Lechleiter. [9] [10]

Contents

Lechleiter first participated in laboratory research in a summer research program at the University of Minnesota in 1974. [7] Lechleiter received a Bachelor of Science in Chemistry from Xavier University in 1975. [4] He went on to receive a master's degree and a PhD in organic chemistry from Harvard University in 1980 after studying on a National Science Foundation Fellowship. [11] His thesis advisor was Dr. Paul A. Wender. [9]

John C. Lechleiter and his wife Sarah live in Indianapolis, Indiana, have three children, Andrew, Daniel and Elizabeth, and several grandchildren. [9]

Career

Lechleiter joined Eli Lilly and company in 1979 as senior organic chemist. [1] [2] [3] [5] [7] From 1984 to 1986, he served as director of pharmaceutical product development at the Lilly Research Centre Limited in Windlesham, England. [1] [2] [3] In 1986, he returned to the US as manager of research and development projects for Europe. [1] [2] [3] He became Director of development projects management in 1988, Executive Director of pharmaceutical product development in 1991, Vice President of pharmaceutical product development in 1993, and Vice President of regulatory affairs in 1994. Lechleiter became Vice President for development and regulatory affairs in 1996, and Senior Vice President of pharmaceutical products in 1998. [1] [2] [3] In 2001, he was appointed Executive Vice President for pharmaceutical products and corporate development. [1] [2] [3] In a 2003 e-mail, he discussed the use of the anti-schizophrenia or bipolar disorder drug Zyprexa for "disruptive kids",(an "off-label" use, for which drug manufacturers are not legally permitted to encourage) even if it was not approved by federal regulators because it could lead to diabetes.“The fact we are now talking to child psychs and peds and others about Strattera means that we must seize the opportunity to expand our work with Zyprexa in this same child-adolescent population." [12] In 2004, he became Executive Vice President for pharmaceutical operations. [1] [2] [3]

John Lechleiter served as Lilly's president and chief operating officer beginning in October 2005. He also joined Lilly's Board of Directors at that time. Lechleiter was elected as Lilly’s president and chief executive officer (CEO), effective April 1, 2008. [1] [2] [3] [5] [6] Effective January 1, 2009, Lechleiter was appointed as Chairman of the Board of Directors of Eli Lilly and Company, succeeding Sidney Taurel. [13] In 2012, he earned US$15.57 million. [4] He is credited with successfully guiding the company through a difficult period in which patent protection expired for four of its main products (Gemzar, Zyprexa, Cymbalta and Evista), and for establishing a promising pipeline of possible new drugs. [14] His advice to others is "We like to move quickly, but the most important thing is to be patient, resolute, and be guided by the data." [15]

Lechleiter is a member of the American Chemical Society, the Business Roundtable and The Business Council. [1] [2] [3] He is Chairman of the Pharmaceutical Research and Manufacturers of America and President of the International Federation of Pharmaceutical Manufacturers & Associations. [5] Lechleiter is on the Boards of Directors of Nike, Inc. (from 2009), [6] [16] the Central Indiana Corporate Partnership [17] and the Great Lakes Chemical Corporation. [18]

He has served on the Board of Trustees of his alma mater, Xavier University, for a three-year term beginning in September 2004, [19] and on the board of the Life Sciences Foundation. [20] He serves as a distinguished advisor to the Children's Museum of Indianapolis. [13] [21] In 2014 he became chairman of United Way Worldwide, [22] which Lilly has supported for many years through both corporate giving and volunteerism. [23] Lilly employees are encouraged to participate in the Lilly Global Day of Service, an internationally observed day of charitable work in their communities. Lechleiter began the initiative in 2008, the year that he became CEO. [9] [24] [25] Lechleiter has identified poor K-12 and STEM education as "this country's Achilles' heel", [7] and the Lechleiter family has contributed towards K-12 education via the Catholic Education Foundation of Louisville. [10]

Awards and honors

He has received Honorary Doctorates from Marian University (2006), the University of Indianapolis (2012), and the National University of Ireland (2012). [1] [3] [9]

In 2012, he was awarded the inaugural Global Health Partner Award from Project HOPE. [26] [27]

In 2014, he was named as the August M. Watanabe Life Sciences Champion of the Year for his work in supporting the development of the Indiana Biosciences Research Institute. [20]

In 2015, he received the 2015 International Citizen of the Year Award from the International Center of Indianapolis, Indiana. [28]

Related Research Articles

<span class="mw-page-title-main">Kelley School of Business</span> Business school of Indiana University

<span class="mw-page-title-main">Eli Lilly and Company</span> American pharmaceutical company

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.

<span class="mw-page-title-main">Eli Lilly</span> American pharmacist, Union Army officer, businessman, philanthropist

Eli Lilly was an American soldier, pharmacist, chemist, and businessman who founded the Eli Lilly and Company pharmaceutical corporation. Lilly enlisted in the Union Army during the American Civil War and recruited a company of men to serve with him in the 18th Independent Battery Indiana Light Artillery. He was later promoted to major and then colonel, and was given command of the 9th Regiment Indiana Cavalry. Lilly was captured in September 1864 and held as a prisoner of war until January 1865. After the war, he attempted to run a plantation in Mississippi, but it failed and he returned to his pharmacy profession after the death of his first wife.

<span class="mw-page-title-main">Eli Lilly (industrialist, born 1885)</span> American industrialist and philanthropist

Eli Lilly, sometimes referred to as Eli Lilly Jr. to distinguish him from his grandfather of the same name, was an American pharmaceutical industrialist and philanthropist from Indianapolis, Indiana, United States. During his tenure as head of Eli Lilly and Company, which was founded by his grandfather, the company grew from a successful, family-owned business into a modern corporation and industry leader. Lilly served as the company president (1932–1948), chairman of the board of directors, and honorary chairman of the board.

Lilly Endowment Inc., headquartered in Indianapolis, Indiana, is one of the world's largest private philanthropic foundations and among the largest endowments in the United States. It was founded in 1937 by Josiah K. Lilly Sr. and his sons, Eli Jr. and Josiah Jr. (Joe), with an initial gift of Eli Lilly and Company stock valued at $280,000 USD. As of 2020, its total assets were worth $21 billion.

<span class="mw-page-title-main">Josiah K. Lilly Jr.</span> American businessman and industrialist

Josiah Kirby "Joe" Lilly Jr. was a businessman and industrialist who served as president and chairman of the board (1953–66) of Eli Lilly and Company, the pharmaceutical firm his grandfather, Colonel Eli Lilly, founded in Indianapolis in 1876. Lilly, the younger son and namesake of Josiah K. Lilly Sr., graduated from the University of Michigan's School of Pharmacy in 1914 where he was a member of the Chi Psi Fraternity. He served in the U.S. Army in France during World War I. At Eli Lilly and Company, where his primary focus was marketing and human resources, he served as vice president of marketing, executive vice president of the company, and president of Eli Lilly International Corporation, before succeeded his older brother, Eli Jr., as company president in 1948 and as chairman of the board in 1953.

<span class="mw-page-title-main">Josiah K. Lilly Sr.</span> American businessman

Josiah Kirby Lilly Sr., nicknamed "J. K.," was an American businessman, pharmaceutical industrialist, and philanthropist who became president and chairman of the board of Eli Lilly and Company, the pharmaceutical firm his father, Colonel Eli Lilly, founded in 1876. Josiah, the colonel's sole heir, began working at his father’s company at the age of fourteen. He graduated from the Philadelphia College of Pharmacy and Science and became superintendent of the Lilly laboratories in 1882 and company president in 1898. Under his leadership, the company introduced standardized manufacturing processes, expanded its sales force, and increased its research efforts to develop new drugs. Eli Lilly and Company grew into one of the largest and most influential pharmaceutical corporations in the world, and the largest corporation in Indiana. Lilly’s eldest son, Eli Jr., succeeded him as president in 1932. His younger son, Josiah Jr. ("Joe"), succeeded Eli as company president in 1948. J. K. served as chairman of the board from 1932 until his death in 1948.

<span class="mw-page-title-main">Mark Parker</span> American businessman (born 1955)

Mark Parker is an American businessman. He serves as executive chairman of Nike, Inc. He was named the third CEO of the company in 2006 and served as president and CEO until 13 January 2020. Since April 3, 2023, he has served as chairman of The Walt Disney Company.

<span class="mw-page-title-main">Indiana Historical Society</span> State historical society in Indiana, United States

The Indiana Historical Society (IHS) is one of the United States' oldest and largest historical societies and describes itself as "Indiana's Storyteller".

Sidney Taurel is an Spanish-born American businessman. He is the chairman of Pearson plc and chairman emeritus of Eli Lilly and Company, where he had a 37-year career and served as chairman and chief executive officer from 1998 to 2008. He became chairman of Pearson in January 2016. He is currently a director of IBM Corporation and advises Almirall S.A. on issues of corporate strategy.

<span class="mw-page-title-main">Eli Hurvitz</span>

Eliyahu "Eli" Hurvitz was an Israeli industrialist. He was the chairman of the board and former CEO of Teva Pharmaceutical Industries at the time of his death.

John A. Galloway is an endocrinologist who has made major contributions to the study and treatment of diabetes. He was clinical research fellow and principal physician in charge of diabetes-related research at the Lilly Laboratory for Clinical Research. The holder of four patents and author of over 80 publications, Galloway also served as Professor of Medicine at the Indiana University School of Medicine.

Life Sciences Foundation (LSF) was a San Francisco-based nonprofit organization that was established in 2011 to collect, preserve, interpret, and promote the history of biotechnology. LSF conducted historical research, maintained archives and published historically relevant materials and information.

Charles E. Golden is an American businessman.

Steven M. Paul is an American neuroscientist and pharmaceutical executive. As of 2021, Paul serves as the CEO, president and chairman of Karuna Therapeutics.

<span class="mw-page-title-main">Indiana Biosciences Research Institute</span> Nonprofit organization in Indianapolis, Indiana, U.S.

The Indiana Biosciences Research Institute (IBRI) is an American nonprofit translational research organization headquartered in Indianapolis, Indiana, United States within the 16 Tech Innovation District. The IBRI is the nation's first industry-led collaborative life sciences research institute. Its primary focus is on better understanding the pathogenesis of type 1 and type 2 diabetes to translate this knowledge into novel therapies, while also expanding into other metabolic diseases that share common systems and pathways.

David Andrew Broecker is an American life sciences executive. He was president and CEO of Alkermes from 2007 to 2009 and was appointed president and CEO of the Indiana Biosciences Research Institute in 2015. He left that position in 2017.

<span class="mw-page-title-main">Flumezapine</span> Antipsychotic drug

Flumezapine is an abandoned, investigational antipsychotic drug that was studied for the treatment of schizophrenia. Flumezapine failed clinical trials due to concern for liver and muscle toxicity. Flumezapine is structurally related to the common antipsychotic olanzapine—a point that was used against its manufacturer, Eli Lilly and Company, in a lawsuit in which generic manufacturers sought to void the patent on brand name olanzapine (Zyprexa). Although flumezapine does not differ greatly from olanzapine in terms of its structure, the difference was considered to be non-obvious, and Eli Lilly's patent rights on Zyprexa were upheld.

Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.

Richard "DicK" Wood was an American business executive.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 "Executive Profile: John C. Lechleiter Ph.D." Bloomberg BusinessWeek. Archived from the original on December 24, 2012. Retrieved 24 August 2015.
  2. 1 2 3 4 5 6 7 8 9 10 "John Lechleiter". Wall Street Journal. Retrieved 24 August 2015.
  3. 1 2 3 4 5 6 7 8 9 10 "Executive Committee". Eli Lilly and Company.
  4. 1 2 3 "CEO Compensation #96 John C Lechleiter". Forbes.com. 2012. Retrieved 24 August 2015.
  5. 1 2 3 4 "PhRMA Chairman John Lechleiter: Biography". PhRMA. Pharmaceutical Research and Manufacturers of America. Archived from the original on 8 August 2014. Retrieved 24 August 2015.
  6. 1 2 3 "John C. Lechleiter Joins Nike's Board of Directors". Nike News. June 18, 2009. Retrieved 24 August 2015.
  7. 1 2 3 4 "A Conversation with John Lechleiter". The GSAS Bulletin. Harvard Graduate School of Arts and Sciences. 10 April 2012. Archived from the original on 22 July 2015. Retrieved 24 August 2015.
  8. ↑ "John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor | Eli Lilly and Company". investor.lilly.com. Retrieved 2020-12-28.
  9. 1 2 3 4 5 Maguire, Anita (June 8, 2012). "TEXT OF THE INTRODUCTORY ADDRESS DELIVERED BY: PROFESSOR ANITA MAGUIRE, Vice President for Research & Innovation, University College Cork on 8 June 2012, on the occasion of the conferring of the Degree of Doctor of Science, honoris causa, on JOHN LECHLEITER" (PDF). University College, Cork, Ireland. Retrieved 25 August 2015.
  10. 1 2 "Lechleiter Family to Donate $1 Million to the Catholic Education Foundation of Louisville". Archdiocese of Louisville Press Release. April 23, 2015. Archived from the original on 23 September 2015. Retrieved 25 August 2015.
  11. ↑ "Dr. John C Lechleiter". SCHED. EU Science: Global Challenges Global Collaboration Conference. Retrieved 24 August 2015.
  12. ↑ Berenson, Alex (March 15, 2008). "Eli Lilly E-Mail Discussed Unapproved Use of Drug". The New York Times. Retrieved 24 August 2015.
  13. 1 2 "John Lechleiter Named Chairman of Lilly's Board of Directors". PRNewswire. September 18, 2008. Retrieved 24 August 2015.
  14. ↑ Andrews, Greg (February 14, 2015). "How Eli Lilly CEO Lechleiter pulled company out of long slide". Indianapolis Business Journal. Retrieved 24 August 2015.
  15. ↑ Craig, Victoria (December 11, 2013). "Tales of the 'Accidental CEO': Eli Lilly's Lechleiter". Fox Business. Retrieved 25 August 2015.
  16. ↑ "Corporate Governance". Nike Corporation. Retrieved 25 August 2015.
  17. ↑ "Board of Directors". Central Indiana Corporate Partnership. Retrieved 25 August 2015.
  18. ↑ "Stay current on former Great Lakes Chemical Corporation executives and board members". Great Lakes Chemical Corporation. Equilar Atlas.
  19. ↑ Del Valle, Debora (September 30, 2005). "Xavier University Trustee Named Eli Lilly President and Chief Operating Officer". Xavier University Public Relations. Retrieved 25 August 2015.
  20. 1 2 "Eli Lilly and Company Chairman, President and CEO John C. Lechleiter honored as Watanabe Life Sciences Champion of the Year". BioCrossroads. October 15, 2014. Retrieved 24 August 2015.
  21. ↑ "Board of Trustees". The Children's Museum of Indianapolis. Retrieved 24 August 2015.
  22. ↑ "Lilly CEO elected chairman of United Way Worldwide board". Indianapolis Business Journal. May 14, 2014. Retrieved 24 August 2015.
  23. ↑ McLaughlin, Andrew (November 19, 2013). "Lilly to Present Record-Breaking $12.6 Million Gift to United Way". PRNewsWire. Retrieved 25 August 2015.
  24. ↑ McLaughlin, Andrew (October 29, 2014). "Lilly to Present Record-Breaking $12.7 Million Gift to United Way". PRNewsWire. Retrieved 25 August 2015.
  25. ↑ "Lilly: Seventh Global Day of Service Focuses on Education and Health on Oct. 2 (Indianapolis)". Indiana Chamber. September 25, 2014. Retrieved 25 August 2015.
  26. ↑ Marbaugh, David (June 19, 2012). "Blog and Video: Dr. Lechleiter, Lilly Receive Inaugural Project HOPE Partnership Award". 3BL Media. Retrieved 24 August 2015.
  27. ↑ "Leaders in Global Health Recognized at Inaugural Project HOPE Awards Program". Project Hope. June 12, 2012. Retrieved 24 August 2015.
  28. ↑ "The International Center to Honor John Lechleiter as 2015 International Citizen of the Year". The International Center. April 13, 2015. Archived from the original on 3 October 2015. Retrieved 24 August 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.